{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T16:10:41Z","timestamp":1774455041521,"version":"3.50.1"},"reference-count":135,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1053\/j.ajkd.2008.07.035","type":"journal-article","created":{"date-parts":[[2008,11,10]],"date-time":"2008-11-10T00:34:09Z","timestamp":1226277249000},"page":"994-1009","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Management of Hyperuricemia and Gout in CKD"],"prefix":"10.1053","volume":"52","author":[{"given":"Angelo L.","family":"Gaffo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth G.","family":"Saag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2008.07.035_bib1","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1097\/01.ASN.0000034910.58454.FD","article-title":"A role for uric acid in the progression of renal disease","volume":"13","author":"Kang","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib2","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/jama.287.3.356","article-title":"Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey","volume":"287","author":"Ford","year":"2002","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2008.07.035_bib3","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1161\/01.HYP.0000091371.53502.D3","article-title":"Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation","volume":"42","author":"Masuo","year":"2003","journal-title":"Hypertension"},{"key":"10.1053\/j.ajkd.2008.07.035_bib4","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/0895-4356(94)00244-K","article-title":"The prevalence and prophylaxis of gout in England","volume":"48","author":"Harris","year":"1995","journal-title":"J Clin Epidemiol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib5","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.2165\/00003495-200565180-00004","article-title":"Gout in solid organ transplantation: A challenging clinical problem","volume":"65","author":"Stamp","year":"2005","journal-title":"Drugs"},{"key":"10.1053\/j.ajkd.2008.07.035_bib6","series-title":"Arthritis and Allied Conditions: A Textbook of Rheumatology","first-page":"2303","article-title":"Clinical gout and the pathogenesis of hyperuricemia","author":"Becker","year":"2005"},{"key":"10.1053\/j.ajkd.2008.07.035_bib7","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00559.x","article-title":"Familial juvenile hyperuricemic nephropathy: Detection of mutations in the uromodulin gene in five Japanese families","volume":"65","author":"Kudo","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2008.07.035_bib8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","article-title":"Molecular identification of a renal urate anion exchanger that regulates blood urate levels","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2008.07.035_bib9","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/ar1909","article-title":"Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics","volume":"8","author":"Terkeltaub","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1053\/j.ajkd.2008.07.035_bib10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.ASN.0000105320.04395.D0","article-title":"Clinical and molecular analysis of patients with renal hypouricemia in Japan\u2014Influence of URAT1 gene on urinary urate excretion","volume":"15","author":"Ichida","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib11","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1002\/art.21242","article-title":"A common mutation in an organic anion transporter gene, SLC22A12, is a suppressing factor for the development of gout","volume":"52","author":"Taniguchi","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2008.07.035_bib12","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1172\/JCI12471","article-title":"Functional reconstitution, membrane targeting, genomic structure, and chromosomal localization of a human urate transporter","volume":"107","author":"Lipkowitz","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1053\/j.ajkd.2008.07.035_bib13","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1002\/art.20438","article-title":"Gout: On the brink of novel therapeutic options for an ancient disease","volume":"50","author":"Bieber","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2008.07.035_bib14","series-title":"Arthritis and Allied Conditions: A Textbook of Rheumatology","first-page":"2357","article-title":"Pathogenesis and treatment of crystal-induced inflammation","author":"Terkeltaub","year":"2005"},{"key":"10.1053\/j.ajkd.2008.07.035_bib15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/BF03401822","article-title":"Involvement of macrophage migration inhibitory factor (MIF) in experimental uric acid nephropathy","volume":"6","author":"Kim","year":"2000","journal-title":"Mol Med"},{"key":"10.1053\/j.ajkd.2008.07.035_bib16","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1136\/ard.2007.078014","article-title":"Inflammasome and rheumatic diseases: Evolving concepts","volume":"67","author":"Sidiropoulos","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2008.07.035_bib17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","article-title":"Asymptomatic hyperuricemia","volume":"82","author":"Campion","year":"1987","journal-title":"Am J Med"},{"key":"10.1053\/j.ajkd.2008.07.035_bib18","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/art.22232","article-title":"Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: A prospective study","volume":"55","author":"Perez-Ruiz","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2008.07.035_bib19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/art.20761","article-title":"Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: The Third National Health and Nutrition Examination Survey","volume":"52","author":"Choi","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2008.07.035_bib20","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa035700","article-title":"Purine-rich foods, dairy and protein intake, and the risk of gout in men","volume":"350","author":"Choi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2008.07.035_bib21","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/art.20821","article-title":"Beer, liquor, and wine consumption and serum uric acid level: The Third National Health and Nutrition Examination Survey","volume":"51","author":"Choi","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2008.07.035_bib22","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(04)16000-5","article-title":"Alcohol intake and risk of incident gout in men: A prospective study","volume":"363","author":"Choi","year":"2004","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2008.07.035_bib23","doi-asserted-by":"crossref","first-page":"800.e13","DOI":"10.1016\/j.amjmed.2006.01.020","article-title":"Alcohol consumption as a trigger of recurrent gout attacks","volume":"119","author":"Zhang","year":"2006","journal-title":"Am J Med"},{"key":"10.1053\/j.ajkd.2008.07.035_bib24","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI103905","article-title":"Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man","volume":"38","author":"Yu","year":"1959","journal-title":"J Clin Invest"},{"key":"10.1053\/j.ajkd.2008.07.035_bib25","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1172\/JCI104817","article-title":"Mutual suppression of the uricosuric effects of sulfinpyrazone and salicylate: A study in interactions between drugs","volume":"42","author":"Yue","year":"1963","journal-title":"J Clin Invest"},{"key":"10.1053\/j.ajkd.2008.07.035_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/1529-0131(200001)43:1<103::AID-ANR13>3.0.CO;2-C","article-title":"The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients","volume":"43","author":"Caspi","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2008.07.035_bib27","first-page":"305","article-title":"Effect of diuretics on the renal handling of urate","volume":"8","author":"Kahn","year":"1988","journal-title":"Semin Nephrol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib28","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1136\/ard.2005.040360","article-title":"Gout, not induced by diuretics?","volume":"65","author":"Janssens","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2008.07.035_bib29","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1111\/tri.1992.5.s1.81","article-title":"Influence of cyclosporin A (CyA) on renal handling of urate","volume":"5","author":"Marcen","year":"1992","journal-title":"Transpl Int"},{"key":"10.1053\/j.ajkd.2008.07.035_bib30","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000189328","article-title":"Mechanisms of hyperuricemia in cyclosporine-treated renal transplanted children","volume":"74","author":"Laine","year":"1996","journal-title":"Nephron"},{"key":"10.1053\/j.ajkd.2008.07.035_bib31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/ndt\/11.1.153","article-title":"Hyperuricaemia in cyclosporin-treated patients: GFR-related effect","volume":"11","author":"Zurcher","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2008.07.035_bib32","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1016\/j.transproceed.2005.08.042","article-title":"Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients","volume":"37","author":"Kanbay","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1053\/j.ajkd.2008.07.035_bib33","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/01.tp.0000188722.84775.af","article-title":"New-onset gout after kidney transplantation: Incidence, risk factors and implications","volume":"80","author":"Abbott","year":"2005","journal-title":"Transplantation"},{"key":"10.1053\/j.ajkd.2008.07.035_bib34","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2165\/00003495-200666120-00002","article-title":"Pathophysiology, clinical presentation and treatment of gout","volume":"66","author":"Teng","year":"2006","journal-title":"Drugs"},{"key":"10.1053\/j.ajkd.2008.07.035_bib35","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1001\/archinte.1993.00410240099012","article-title":"Gout and pseudogout in hospitalized patients","volume":"153","author":"Ho","year":"1993","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.ajkd.2008.07.035_bib36","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/ard.29.5.461","article-title":"Clinical survey of 354 patients with gout","volume":"29","author":"Grahame","year":"1970","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2008.07.035_bib37","first-page":"976","article-title":"Prepatellar bursitis: A unique presentation of tophaceous gout in an normouricemic patient","volume":"24","author":"Dawn","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib38","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0272-6386(12)80995-4","article-title":"Gouty arthritis in end-stage renal disease: Clinical course and rarity of new cases","volume":"23","author":"Ifudu","year":"1994","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2008.07.035_bib39","doi-asserted-by":"crossref","first-page":"756","DOI":"10.7326\/0003-4819-131-10-199911160-00007","article-title":"Synovial fluid analysis for diagnosis of intercritical gout","volume":"131","author":"Pascual","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ajkd.2008.07.035_bib40","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/art.1780160402","article-title":"The past four decades of progress in the knowledge of gout, with an assessment of the present status","volume":"16","author":"Gutman","year":"1973","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2008.07.035_bib41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jemermed.2006.07.019","article-title":"Does the presence of crystal arthritis rule out septic arthritis?","volume":"32","author":"Shah","year":"2007","journal-title":"J Emerg Med"},{"key":"10.1053\/j.ajkd.2008.07.035_bib42","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.56.11.696a","article-title":"Serum uric acid in acute gout","volume":"56","author":"Logan","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2008.07.035_bib43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.23177","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I","volume":"58","author":"Helmick","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2008.07.035_bib44","first-page":"2403","article-title":"Epidemiology of gout: Is the incidence rising?","volume":"29","author":"Arromdee","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib45","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II","volume":"58","author":"Lawrence","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2008.07.035_bib46","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/ard.2004.024091","article-title":"Gout epidemiology: Results from the UK General Practice Research Database, 1990-1999","volume":"64","author":"Mikuls","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2008.07.035_bib47","first-page":"1595","article-title":"The epidemiology of gout and hyperuricemia in a rural population of Java","volume":"19","author":"Darmawan","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib48","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1136\/ard.37.5.466","article-title":"A prospective study of gout in New Zealand Maoris","volume":"37","author":"Brauer","year":"1978","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2008.07.035_bib49","first-page":"1346","article-title":"The prevalence of hyperuricemia in a population of the coastal city of Qingdao, China","volume":"33","author":"Nan","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib50","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2169\/internalmedicine.44.706","article-title":"Frequency of gouty arthritis in patients with end-stage renal disease in Japan","volume":"44","author":"Ohno","year":"2005","journal-title":"Intern Med"},{"key":"10.1053\/j.ajkd.2008.07.035_bib51","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1440-1797.2006.00577.x","article-title":"Gout in renal transplant recipients","volume":"11","author":"Stamp","year":"2006","journal-title":"Nephrology (Carlton)"},{"key":"10.1053\/j.ajkd.2008.07.035_bib52","first-page":"1422","article-title":"Ketoprofen versus indomethacin in patients with acute gouty arthritis: A multicenter, double blind comparative study","volume":"15","author":"Altman","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib53","first-page":"297","article-title":"Sulindac in the treatment of acute gout arthritis","volume":"4","author":"Karachalios","year":"1982","journal-title":"Int J Tissue React"},{"key":"10.1053\/j.ajkd.2008.07.035_bib54","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0196-0644(95)70037-4","article-title":"Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis","volume":"26","author":"Shrestha","year":"1995","journal-title":"Ann Emerg Med"},{"key":"10.1053\/j.ajkd.2008.07.035_bib55","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/ard.36.1.80","article-title":"Multicentre trial of naproxen and phenylbutazone in acute gout","volume":"36","author":"Sturge","year":"1977","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2008.07.035_bib56","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/bmj.324.7352.1488","article-title":"Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis","volume":"324","author":"Schumacher","year":"2002","journal-title":"BMJ"},{"key":"10.1053\/j.ajkd.2008.07.035_bib57","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/kem090","article-title":"Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout","volume":"46","author":"Willburger","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1053\/j.ajkd.2008.07.035_bib58","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1445-5994.1987.tb01232.x","article-title":"Does colchicine work?","volume":"17","author":"Ahern","year":"1987","journal-title":"Aust N Z J Med"},{"key":"10.1053\/j.ajkd.2008.07.035_bib59","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0736-4679(02)00430-4","article-title":"Deaths associated with inappropriate intravenous colchicine administration","volume":"22","author":"Bonnel","year":"2002","journal-title":"J Emerg Med"},{"key":"10.1053\/j.ajkd.2008.07.035_bib60","first-page":"150","article-title":"Current aspects of colchicine therapy\u2014Classical indications and new therapeutic uses","volume":"6","author":"Lange","year":"2001","journal-title":"Eur J Med Res"},{"key":"10.1053\/j.ajkd.2008.07.035_bib61","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0049-0172(90)90070-V","article-title":"Systemic steroid therapy for acute gout: A clinical trial and review of the literature","volume":"19","author":"Groff","year":"1990","journal-title":"Semin Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2008.07.035_bib62","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.annemergmed.2006.11.014","article-title":"Comparison of oral prednisolone\/paracetamol and oral indomethacin\/paracetamol combination therapy in the treatment of acute goutlike arthritis: A double-blind, randomized, controlled trial","volume":"49","author":"Man","year":"2007","journal-title":"Ann Emerg Med"},{"key":"10.1053\/j.ajkd.2008.07.035_bib63","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1345\/aph.10230","article-title":"Corticotropin for acute management of gout","volume":"35","author":"Taylor","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1053\/j.ajkd.2008.07.035_bib64","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1002\/art.10526","article-title":"Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis","volume":"46","author":"Getting","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2008.07.035_bib65","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/art.1780310618","article-title":"Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout","volume":"31","author":"Axelrod","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2008.07.035_bib66","first-page":"696","article-title":"ACTH revisited: Effective treatment for acute crystal induced synovitis in patients with multiple medical problems","volume":"21","author":"Ritter","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib67","first-page":"1325","article-title":"Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis","volume":"21","author":"Siegel","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib68","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJM199602153340707","article-title":"The management of gout","volume":"334","author":"Emmerson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2008.07.035_bib69","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib70","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2008.07.035_bib71","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1124\/pr.58.1.6","article-title":"Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1053\/j.ajkd.2008.07.035_bib72","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2125.1988.tb03401.x","article-title":"Allopurinol dosage selection: Relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion","volume":"26","author":"Day","year":"1988","journal-title":"Br J Clin Pharmacol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib73","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","article-title":"Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia","volume":"57","author":"Perez-Ruiz","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2008.07.035_bib74","first-page":"1575","article-title":"Compliance with allopurinol therapy among managed care enrollees with gout: A retrospective analysis of administrative claims","volume":"31","author":"Riedel","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib75","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/1529-0131(200101)44:1<231::AID-ANR30>3.0.CO;2-7","article-title":"Efficacy and safety of desensitization to allopurinol following cutaneous reactions","volume":"44","author":"Fam","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2008.07.035_bib76","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1053\/j.ajkd.2008.07.035_bib77","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/art.1780310318","article-title":"Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxypurinol","volume":"31","author":"Emmerson","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2008.07.035_bib78","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.ajkd.2008.07.035_bib79","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0190-9622(79)70031-4","article-title":"The allopurinol hypersensitivity syndrome","volume":"1","author":"Lupton","year":"1979","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib80","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/art.1780290111","article-title":"The allopurinol hypersensitivity syndrome","volume":"29","author":"Singer","year":"1986","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2008.07.035_bib81","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.1974.00320210163026","article-title":"Severe allopurinol hypersensitivity","volume":"134","author":"Young","year":"1974","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.ajkd.2008.07.035_bib82","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/jama.1979.03300040043027","article-title":"Management of gout","volume":"242","author":"Fox","year":"1979","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2008.07.035_bib83","series-title":"Arthritis and Allied Conditions: A Textbook of Rheumatology","first-page":"2341","article-title":"Management of hyperuricemia","author":"Hahn","year":"2005"},{"key":"10.1053\/j.ajkd.2008.07.035_bib84","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2165\/00002018-199411040-00004","article-title":"Risks and benefits of drugs used in the management and prevention of gout","volume":"11","author":"Conaghan","year":"1994","journal-title":"Drug Saf"},{"key":"10.1053\/j.ajkd.2008.07.035_bib85","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/ndt\/gfl798","article-title":"Probenecid-induced membranous nephropathy","volume":"22","author":"Izzedine","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2008.07.035_bib86","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1081\/NCN-200027372","article-title":"Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers","volume":"23","author":"Becker","year":"2004","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1053\/j.ajkd.2008.07.035_bib87","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00045391-200501000-00005","article-title":"Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment","volume":"12","author":"Mayer","year":"2005","journal-title":"Am J Ther"},{"key":"10.1053\/j.ajkd.2008.07.035_bib88","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2008.07.035_bib89","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1345\/aph.1H121","article-title":"Febuxostat: A selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout","volume":"40","author":"Bruce","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1053\/j.ajkd.2008.07.035_bib90","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1200\/JCO.2003.04.115","volume":"21","author":"Coiffier","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib91","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/sj.leu.2400850","article-title":"Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies","volume":"11","author":"Pui","year":"1997","journal-title":"Leukemia"},{"key":"10.1053\/j.ajkd.2008.07.035_bib92","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2001.19.3.697","article-title":"Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma","volume":"19","author":"Pui","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib93","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/ndt\/gfh629","article-title":"Urate oxidase (rasburicase) for treatment of severe tophaceous gout","volume":"20","author":"Vogt","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2008.07.035_bib94","first-page":"1942","article-title":"Uricase formulated with polyethylene glycol (uricase-PEG 20): Biochemical rationale and preclinical studies","volume":"29","author":"Bomalaski","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib95","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1053\/j.ajkd.2008.07.035_bib96","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/art.22403","article-title":"Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout","volume":"56","author":"Sundy","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2008.07.035_bib97","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.addr.2007.06.011","article-title":"PEG-uricase in the management of treatment-resistant gout and hyperuricemia","volume":"60","author":"Sherman","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1053\/j.ajkd.2008.07.035_bib98","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0025-7125(16)35113-6","article-title":"The kidney of gout, a clinical entity","volume":"21","author":"Modern","year":"1952","journal-title":"Med Clin North Am"},{"key":"10.1053\/j.ajkd.2008.07.035_bib99","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00005792-196012000-00001","article-title":"The kidney in gout","volume":"39","author":"Talbott","year":"1960","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.ajkd.2008.07.035_bib100","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.semnephrol.2004.10.001","article-title":"Uric acid and chronic renal disease: Possible implication of hyperuricemia on progression of renal disease","volume":"25","author":"Kang","year":"2005","journal-title":"Semin Nephrol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib101","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0272-6386(04)00934-5","article-title":"Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort","volume":"44","author":"Iseki","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2008.07.035_bib102","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1291\/hypres.24.691","article-title":"Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects","volume":"24","author":"Iseki","year":"2001","journal-title":"Hypertens Res"},{"key":"10.1053\/j.ajkd.2008.07.035_bib103","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1291\/hypres.27.835","article-title":"Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan","volume":"27","author":"Nagahama","year":"2004","journal-title":"Hypertens Res"},{"key":"10.1053\/j.ajkd.2008.07.035_bib104","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2188\/jea.10.403","article-title":"Does hyperuricemia affect mortality?","volume":"10","author":"Tomita","year":"2000","journal-title":"J Epidemiol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib105","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000045939","article-title":"Serum uric acid and renal prognosis in patients with IgA nephropathy","volume":"87","author":"Ohno","year":"2001","journal-title":"Nephron"},{"key":"10.1053\/j.ajkd.2008.07.035_bib106","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/ndt\/15.1.34","article-title":"Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy","volume":"15","author":"Syrjanen","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2008.07.035_bib107","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1111\/j.1523-1755.2005.00273.x","article-title":"Hyperuricemia induces endothelial dysfunction","volume":"67","author":"Khosla","year":"2005","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2008.07.035_bib108","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/hy1101.092839","article-title":"Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism","volume":"38","author":"Mazzali","year":"2001","journal-title":"Hypertension"},{"key":"10.1053\/j.ajkd.2008.07.035_bib109","doi-asserted-by":"crossref","first-page":"F991","DOI":"10.1152\/ajprenal.00283.2001","article-title":"Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism","volume":"282","author":"Mazzali","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib110","doi-asserted-by":"crossref","first-page":"F1105","DOI":"10.1152\/ajprenal.00170.2002","article-title":"Mild hyperuricemia induces glomerular hypertension in normal rats","volume":"283","author":"Sanchez-Lozada","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib111","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/ndt\/gfm783","article-title":"Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia","volume":"23","author":"Sanchez-Lozada","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2008.07.035_bib112","doi-asserted-by":"crossref","first-page":"F710","DOI":"10.1152\/ajprenal.00454.2007","article-title":"Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome","volume":"294","author":"Sanchez-Lozada","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib113","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","article-title":"Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level","volume":"47","author":"Siu","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2008.07.035_bib114","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/ki.1986.179","article-title":"Requiem for gouty nephropathy","volume":"30","author":"Beck","year":"1986","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2008.07.035_bib115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000168799","article-title":"Renal function in gout patients","volume":"15","author":"Tarng","year":"1995","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib116","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/0002-9343(75)90222-3","article-title":"Renal function in gout","volume":"59","author":"Berger","year":"1975","journal-title":"Am J Med"},{"key":"10.1053\/j.ajkd.2008.07.035_bib117","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0002-9343(79)90076-7","article-title":"Renal outcomes of gout and hyperuricemia","volume":"67","author":"Fessel","year":"1979","journal-title":"Am J Med"},{"key":"10.1053\/j.ajkd.2008.07.035_bib118","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1161\/01.CIR.0000065637.10517.A0","article-title":"Uric acid and survival in chronic heart failure: Validation and application in metabolic, functional, and hemodynamic staging","volume":"107","author":"Anker","year":"2003","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2008.07.035_bib119","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.2337\/diacare.23.9.1242","article-title":"Features of the metabolic syndrome predict higher risk of diabetes and impaired glucose tolerance: A prospective study in Mauritius","volume":"23","author":"Boyko","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ajkd.2008.07.035_bib120","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1515\/JPEM.2003.16.9.1225","article-title":"Serum uric acid levels in obese children and adolescents: Linkage to testosterone levels and pre-metabolic syndrome","volume":"16","author":"Denzer","year":"2003","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1053\/j.ajkd.2008.07.035_bib121","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1161\/01.HYP.0000085858.66548.59","article-title":"Hyperuricemia in childhood primary hypertension","volume":"42","author":"Feig","year":"2003","journal-title":"Hypertension"},{"key":"10.1053\/j.ajkd.2008.07.035_bib122","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2165\/00129784-200303050-00001","article-title":"Hyperuricemia and adverse outcomes in cardiovascular disease: Potential for therapeutic intervention","volume":"3","author":"Gavin","year":"2003","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1053\/j.ajkd.2008.07.035_bib123","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/ije\/28.5.888","article-title":"Risk factors for the incidence of hyperuricaemia: A 6-year longitudinal study of middle-aged Japanese men","volume":"28","author":"Nakanishi","year":"1999","journal-title":"Int J Epidemiol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib124","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMcp030733","article-title":"Clinical practice","volume":"349","author":"Terkeltaub","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2008.07.035_bib125","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1046\/j.1525-139X.2003.16091.x","article-title":"Safety of colchicine in dialysis patients","volume":"16","author":"Anderson-Haag","year":"2003","journal-title":"Semin Dial"},{"key":"10.1053\/j.ajkd.2008.07.035_bib126","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1525-139X.2007.00270.x","article-title":"Allopurinol dosing in renal impairment: Walking the tightrope between adequate urate lowering and adverse events","volume":"20","author":"Dalbeth","year":"2007","journal-title":"Semin Dial"},{"key":"10.1053\/j.ajkd.2008.07.035_bib127","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout","volume":"33","author":"Dalbeth","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1053\/j.ajkd.2008.07.035_bib128","first-page":"179","article-title":"Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients?","volume":"11","author":"De Angelis","year":"2007","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1053\/j.ajkd.2008.07.035_bib129","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1056\/NEJM198908033210504","article-title":"Cyclosporine-induced hyperuricemia and gout","volume":"321","author":"Lin","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2008.07.035_bib130","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/00007890-199107000-00013","article-title":"Renal handling of urate and the incidence of gouty arthritis during cyclosporine and diuretic use","volume":"52","author":"Noordzij","year":"1991","journal-title":"Transplantation"},{"key":"10.1053\/j.ajkd.2008.07.035_bib131","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0002-9610(88)80196-X","article-title":"Hyperuricemia after renal transplantation","volume":"156","author":"Gores","year":"1988","journal-title":"Am J Surg"},{"key":"10.1053\/j.ajkd.2008.07.035_bib132","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0272-6386(87)80103-8","article-title":"The incidence of gout in renal transplant recipients","volume":"10","author":"West","year":"1987","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2008.07.035_bib133","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1097\/00007890-199710150-00027","article-title":"Safety of the mycophenolate mofetil-allopurinol combination in kidney transplant recipients with gout","volume":"64","author":"Jacobs","year":"1997","journal-title":"Transplantation"},{"key":"10.1053\/j.ajkd.2008.07.035_bib134","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000057624","article-title":"Safety of the allopurinol-mycophenolate mofetil combination in the treatment of hyperuricemia of kidney transplant recipients","volume":"91","author":"Navascues","year":"2002","journal-title":"Nephron"},{"key":"10.1053\/j.ajkd.2008.07.035_bib135","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0303-8467(97)00092-9","article-title":"Acute onset of colchicine myoneuropathy in cardiac transplant recipients: Case studies of three patients","volume":"99","author":"Rana","year":"1997","journal-title":"Clin Neurol Neurosurg"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638608012316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638608012316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:50:56Z","timestamp":1759456256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638608012316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":135,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0272638608012316"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2008.07.035","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Hyperuricemia and Gout in CKD","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2008.07.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}